Home Healthcare Pharmaceuticals Irritable Bowel Syndrome Treatment Market

Irritable Bowel Syndrome Treatment Market Size, Share & Trends Analysis Report By Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, Others), By Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), Mixed IBS), By Distribution Channel (Hospitals pharmacies, Drug Stores and Retail Pharmacies, Online pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format: | Report Code: SR5233DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Table Of Content

  1. Executive Summary
  2. Research Scope & Segmentation
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
  3. Market Opportunity Assessment
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
  4. Market Trends
    1. Drivers
    2. Market Warning Factors
    3. Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
  5. Market Assessment
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
  6. Irritable Bowel Syndrome Treatment Market Size Analysis
    1. Introduction
    2. Irritable Bowel Syndrome Treatment Market Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
      1. Rifaximin
      2. Eluxadoline
      3. Lubiprostone
      4. Linaclotide
      5. Others
    3. Irritable Bowel Syndrome Treatment Market Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
      1. IBS with Diarrhea (IBS-D)
      2. IBS with Constipation (IBS-C)
      3. Mixed IBS
    4. Irritable Bowel Syndrome Treatment Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospitals pharmacies
      2. Drug Stores and Retail Pharmacies
      3. Online pharmacies
  7. North America Irritable Bowel Syndrome Treatment Market Size Analysis
    1. Introduction
    2. Irritable Bowel Syndrome Treatment Market Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
      1. Rifaximin
      2. Eluxadoline
      3. Lubiprostone
      4. Linaclotide
      5. Others
    3. Irritable Bowel Syndrome Treatment Market Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
      1. IBS with Diarrhea (IBS-D)
      2. IBS with Constipation (IBS-C)
      3. Mixed IBS
    4. Irritable Bowel Syndrome Treatment Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospitals pharmacies
      2. Drug Stores and Retail Pharmacies
      3. Online pharmacies
    5. U.S.
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    6. Canada
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
  8. Europe Irritable Bowel Syndrome Treatment Market Size Analysis
    1. Introduction
    2. Irritable Bowel Syndrome Treatment Market Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
      1. Rifaximin
      2. Eluxadoline
      3. Lubiprostone
      4. Linaclotide
      5. Others
    3. Irritable Bowel Syndrome Treatment Market Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
      1. IBS with Diarrhea (IBS-D)
      2. IBS with Constipation (IBS-C)
      3. Mixed IBS
    4. Irritable Bowel Syndrome Treatment Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospitals pharmacies
      2. Drug Stores and Retail Pharmacies
      3. Online pharmacies
    5. U.K.
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    6. Germany
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    7. France
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    8. Spain
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    9. Italy
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    10. Russia
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    11. Nordic
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    12. Benelux
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    13. Rest of Europe
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
  9. APAC Irritable Bowel Syndrome Treatment Market Size Analysis
    1. Introduction
    2. Irritable Bowel Syndrome Treatment Market Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
      1. Rifaximin
      2. Eluxadoline
      3. Lubiprostone
      4. Linaclotide
      5. Others
    3. Irritable Bowel Syndrome Treatment Market Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
      1. IBS with Diarrhea (IBS-D)
      2. IBS with Constipation (IBS-C)
      3. Mixed IBS
    4. Irritable Bowel Syndrome Treatment Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospitals pharmacies
      2. Drug Stores and Retail Pharmacies
      3. Online pharmacies
    5. China
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    6. Korea
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    7. Japan
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    8. India
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    9. Australia
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    10. Singapore
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    11. Taiwan
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    12. South East Asia
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    13. Rest of Asia-Pacific
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
  10. Middle East and Africa Irritable Bowel Syndrome Treatment Market Size Analysis
    1. Introduction
    2. Irritable Bowel Syndrome Treatment Market Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
      1. Rifaximin
      2. Eluxadoline
      3. Lubiprostone
      4. Linaclotide
      5. Others
    3. Irritable Bowel Syndrome Treatment Market Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
      1. IBS with Diarrhea (IBS-D)
      2. IBS with Constipation (IBS-C)
      3. Mixed IBS
    4. Irritable Bowel Syndrome Treatment Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospitals pharmacies
      2. Drug Stores and Retail Pharmacies
      3. Online pharmacies
    5. UAE
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    6. Turkey
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    7. Saudi Arabia
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    8. South Africa
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    9. Egypt
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    10. Nigeria
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    11. Rest of MEA
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
  11. LATAM Irritable Bowel Syndrome Treatment Market Size Analysis
    1. Introduction
    2. Irritable Bowel Syndrome Treatment Market Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
      1. Rifaximin
      2. Eluxadoline
      3. Lubiprostone
      4. Linaclotide
      5. Others
    3. Irritable Bowel Syndrome Treatment Market Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
      1. IBS with Diarrhea (IBS-D)
      2. IBS with Constipation (IBS-C)
      3. Mixed IBS
    4. Irritable Bowel Syndrome Treatment Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospitals pharmacies
      2. Drug Stores and Retail Pharmacies
      3. Online pharmacies
    5. Brazil
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    6. Mexico
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    7. Argentina
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    8. Chile
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    9. Colombia
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
    10. Rest of LATAM
      1. Introduction
      2. Market Size & Forecast By Product 2022-2034 (USD MILLION/ Units)
        1. Rifaximin
        2. Eluxadoline
        3. Lubiprostone
        4. Linaclotide
        5. Others
      3. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. IBS with Diarrhea (IBS-D)
        2. IBS with Constipation (IBS-C)
        3. Mixed IBS
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online pharmacies
  12. Competitive Landscape
    1. Irritable Bowel Syndrome Treatment Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    3. Tier Structure Analysis
    4. Recent Developments
  13. Market Players Assessment
    1. Abbott
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Synergy Pharma
    3. Mallinckrodt
    4. Bausch Health Companies Inc.
    5. Ardelyx
    6. Astellas Pharma Inc.
    7. Novartis AG, GSK plc.
    8. Ironwood Pharmaceuticals, Inc.
    9. Takeda Pharmaceutical Company Limited.
  14. Research Methodology
    1. Research Data
      1. Secondary Data
        1. Major Secondary Sources
        2. Key Data from Secondary Sources
      2. Primary Data
        1. Key Data from Primary Sources
        2. Breakdown of Primaries
      3. Secondary And Primary Research
        1. Key Industry Insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
  15. Appendix
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  16. Disclaimer
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.